455 Mission Bay Blvd South
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
445 articles with Nektar Therapeutics
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the third quarter on Wednesday, November 6, 2019, after the close of U.S.-based financial markets.
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with atopic dermatitis.
Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nektar Therapeutics (Nasdaq: NKTR) today announced the acceptance of five clinical and preclinical data abstracts for its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nektar Therapeutics announced several promotions on its executive leadership team
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics.
Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Analyst conference call with breast cancer specialist to be held at 2:30 p.m. Central European Summer Time (CEST)/8:30 a.m. Eastern Daylight Time (EDT)
Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference
Nektar Therapeutics (Nasdaq: NKTR) today announced that new data from a cohort of patients with metastatic triple-negative breast cancer who were enrolled in the PIVOT-02 study will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference, which is being held from September 25 to September 28, 2019
ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the "Class Period")
INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2019
Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/nktr.
Wrapping up the month of August, there are technically four PDUFA dates on the calendar, although one was approved two months early and another may be delayed as the U.S. Food and Drug Administration reevaluates its policies regarding opioid pain medications. Here’s a look.
Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 Program
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in t...
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Nektar Therapeutics and Bristol-Myers Squibb announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo® for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of U.S.-based financial markets.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
Nektar Therapeutics announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in clinical development for the treatment of autoimmune and other chronic inflammatory conditions.
Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
Nektar Therapeutics announced that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00 a.m. EDT during EULAR 2019.
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to lo...
Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting
Nektar Therapeutics announced that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology Meeting in Chicago, Illinois.